--- title: "Onconetix 2025 10-K: Revenue $0.82M, EPS $(16.56)" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/279091956.md" description: "Onconetix reported 2025 revenue of $0.82 million, a 67.7% decline from 2024, with a net loss per share of $(16.56). The company is shifting focus to commercialize Proclarix, halting vaccine programs. Despite lower revenue, improvements in operating and net loss were noted due to cost reductions. Proclarix is CE-marked in the EU and has a U.S. license for an LDT pathway. The company is streamlining operations to conserve resources, with product sales steady at approximately $0.2 million." datetime: "2026-03-13T20:55:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279091956.md) - [en](https://longbridge.com/en/news/279091956.md) - [zh-HK](https://longbridge.com/zh-HK/news/279091956.md) --- > 支持的语言: [English](https://longbridge.com/en/news/279091956.md) | [繁體中文](https://longbridge.com/zh-HK/news/279091956.md) # Onconetix 2025 10-K: Revenue $0.82M, EPS $(16.56) Onconetix reported 2025 revenue of $0.82 million and a net loss per share of $(16.56) as disclosed in its Form 10-K, reflecting a steep revenue decline tied to the completion of prior development services and a company-wide shift to commercialization. Despite lower top-line results, the company posted improvements in operating loss and net loss versus 2024 driven by cost reductions and strategic refocusing. The filing outlines a move to commercialize Proclarix while streamlining operations to conserve resources. **Financial Highlights** - **Revenue**: $0.82 million, decreased $1.71 million (−67.7%) versus 2024 (Part II, Item 8 and MD&A). - **Gross Profit**: $0.63 million, down $0.42 million (−40.0%) versus 2024 (Part II, Item 8 and MD&A). - **Operating Income (Loss)**: $(17.86) million, an improvement of $38.63 million (−68.4%) versus 2024 (Part II, Item 8). - **Net Income (Net loss)**: $(14.03) million, improved $44.66 million (−76.1%) versus 2024 (Part II, Item 8). - **Net Income Per Share**: $(16.56) (basic and diluted); weighted average shares 937,690 (Part II, Item 8). **Business Highlights** - **Commercial Focus Shift**: The company transitioned to a commercial stage, halting its vaccine programs to concentrate resources on commercializing Proclarix. - **Revenue Trend**: The decline in 2025 revenue was driven by the completion of 2024 development services; product sales remained steady at approximately $0.2 million. - **Market Access & Partnerships**: Proclarix is CE-marked in the EU; the company holds an exclusive LabCorp U.S. license for an LDT pathway and is collaborating on a PRIME validation study. - **Operational Streamlining**: Management implemented cost reductions including headcount reductions, terminated ENTADFI commercialization, and recorded related asset impairments to conserve resources. - **Commercial Readiness**: Proclarix is designed for easy laboratory integration (ELISA) targeting PSA 'grey zone' patients with rapid risk scoring to support diagnostic decision-making. Original SEC Filing: Onconetix, Inc. \[ ONCO \] - 10-K - Mar. 13, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### 相关股票 - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [Onconetix (ONCO.US)](https://longbridge.com/zh-CN/quote/ONCO.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) ## 相关资讯与研究 - [Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update](https://longbridge.com/zh-CN/news/281525623.md) - [Oncotelic Subsidiary Showcases Deciparticle Platform at BIO-Europe](https://longbridge.com/zh-CN/news/281062590.md) - [MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation | VATE Stock News](https://longbridge.com/zh-CN/news/281183004.md) - [Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says](https://longbridge.com/zh-CN/news/281049788.md) - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-CN/news/281015927.md)